The functions and signalling mechanisms of the Ang-(1-7) [angiotensin-(1-7)] receptor Mas have been studied extensively. However, less attention has been paid to the intracellular regulation of Mas protein. In the present study, PSD95 (postsynaptic density 95), a novel binding protein of Mas receptor, was identified, and their association was characterized further. Mas specifically interacts with PDZ1-2, but not the PDZ3, domain of PSD95 via Mas-CT (Mas C-terminus), and the last four amino acids [ETVV (Glu-Thr-Val-Val)] of Mas-CT were determined to be essential for this interaction, as shown by GST pull-down, co-immunoprecipitation and confocal colocalization experiments. Gain-of-function and loss-of-function studies indicated that PSD95 enhanced Mas protein expression by increasing the stabilization of the receptor. Mas degradation was robustly inhibited by the proteasome inhibitor MG132 in time-and dose-dependent manners, and the expression of PSD95 impaired Mas ubiquitination, indicating that the PSD95-Mas association inhibits Mas receptor degradation via the ubiquitinproteasome proteolytic pathway. These findings reveal a novel mechanism of Mas receptor regulation by which its expression is modulated at the post-translational level by ubiquitination, and clarify the role of PSD95, which binds directly to Mas, blocking the ubiquitination and subsequent degradation of the receptor via the ubiquitin-proteasome proteolytic pathway.
INTRODUCTION
The renin-angiotensin system is one of the most comprehensively researched and clinically relevant homoeostatic systems in human physiology. As an important bioactive peptide of the reninangiotensin system, Ang-(1-7) [angiotensin- (1) (2) (3) (4) (5) (6) (7) ] is involved in many biological processes such as neural plasticity, memory and anxiety, and possesses anti-angiogenesis, vasodilatation, antiproliferation, anti-fibrosis, anti-hypertrophy and anti-thrombosis properties via a direct interaction with its special receptor Mas [1] [2] [3] [4] [5] .
In the brain, the Mas receptor is critical for certain properties of the central nervous system, including neural plasticity, memory and anxiety. Studies have shown that brief seizure episodes lead to a significant and transient increase in Mas mRNA expression in the hippocampus using in situ hybridization and RNase protection assays [6] . The genetic deletion of Mas abolishes the enhancement of LTP (long-term potentiation) induced by Ang-(1-7) in the CA1 region of the hippocampus, implicating its important function in learning and memory mechanisms [7] . Alterations of spatial learning and anxiety behaviours in Mas-deficient mice are demonstrated by their performance in the elevated plus maze task and the Morris water maze [8] . In addition, the regulation of the brain Mas receptor has a direct impact on cardiovascular diseases including hypertension and heart disease. In sinoaortic denervated rats, the release of hypothalamic Ang-(1-7) can activate the Mas receptor and cause a reduction in blood pressure [9] .
The critical role of Ang-(1-7) in many signalling pathways through its association with the Mas receptor has been reported in several studies. Genetic ablation of Mas abolishes Ang-(1-7)-mediated vasodilation of the aorta, resulting in impaired heart function [10, 11] . Activation of the Mas receptor by Ang-(1-7) stimulates nitric oxide release from endothelial cells, which involves the PI3K (phosphoinositide 3-kinase)-Akt axis, causing vasodilation, inhibition of cell growth and blocking AT1R [AngII (angiotensin II) type 1 receptor]-mediated vasoconstriction [12, 13] . In mouse bone-marrow-derived dendritic cells, Ang-(1-7) enhances AngII-induced phosphorylation of ERK1/2 (extracellular-signal-regulated kinase 1/2) [14] . Ang-(1-7) also inhibits AngII-induced smooth muscle cell proliferation and migration through negative modulation of AngII-induced ERK1/2 activation [15] . Rabelo et al. [13] reported that Ang-(1-7) acts through the receptor Mas to counteract AngII-and AT1R-dependent c-Src activation, ERK1/2 phosphorylation and the generation of ROS (reactive oxygen species) in human endothelial cells [13] .
Most studies on the Mas receptor have focused on its molecular mechanisms and physiological functions, but much less attention has been paid to the intracellular regulation of Mas receptor signalling and its post-translational modification. The Mas gene Abbreviations used: Ang-(1-7), angiotensin-(1-7); AngII, angiotensin II; β 1 AR, β 1 -adrenergic receptor; AT1R, AngII type 1 receptor; BHK, baby-hamster kidney; CHX, cycloheximide; CT, C-terminus; DMEM, Dulbecco's modified Eagle's medium; ERK1/2, extracellular-signal-regulated kinase 1/2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GPCR, G-protein-coupled receptor; HRP, horseradish peroxidase; LTP, long-term potentiation; nNOS, neuronal nitric oxide synthase; PI3K, phosphoinositide 3-kinase; PSD95, postsynaptic density 95; PTEN, phosphatase and tensin homologue deleted on chromosome 10; qPCR, quantitative real-time PCR; SHR, spontaneously hypertensive rat; WKY, Wistar Kyoto; wt, wild-type. 1 These authors contributed equally to this work. 2 Present address: Department of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. 3 To whom correspondence should be addressed (email jq_he@ccmu.edu.cn).
encodes a protein belonging to the classic family of GPCRs (G-protein-coupled receptors) characterized by seven transmembrane domains [16] . The activation of GPCRs is generally regulated by post-translational modifications and/or association of the receptor with its binding molecules [17] . Ubiquitination, acylation and phosphorylation are some of the most common posttranslational modifications involved in GPCR overall expression, subcellular trafficking and signalling. However, there are currently no reports on the post-translational modification of the Mas receptor or the intracellular regulation of Mas signalling.
Investigating the Mas receptor-binding molecules and its posttranslational modifications are therefore of great interest. The Mas receptor contains a conserved typical PDZ domainbinding motif [ETVV (Glu-Thr-Val-Val)] at its CT (C-terminus). PDZ domains are modular protein-interaction domains and play important roles in receptor signalling and functions [18, 19] . In the present study, we identified PSD95 (postsynaptic density 95) associated with the Mas receptor, and the stabilization of the Mas receptor is regulated by PSD95 via direct interaction and possibly through the inhibition of Mas ubiquitination.
MATERIALS AND METHODS

Preparation of plasmids
The pET30A vectors encoding individual PDZ domains of PSD95, pCGN-HA-Mas and pGW-myc-PSD95 constructs were kindly provided by Dr Randy Hall (Emory University, Atlanta, GA, U.S.A.). The wt (wild-type) and its mutant (V325A) of human Mas were amplified by PCR from the pCGN-HA-Mas construct and subcloned into pcDNA3-FLAG and pEGFP-C1 expression vectors respectively. The CT of Mas (the last 27 amino acids of Mas, Mas-CT) wt and its various mutants were amplified by PCR from the pCGN-HA-Mas construct and subcloned into pGEX-4T-1. All of the DNA constructs were individually verified by DNA sequencing.
Western blotting and antibodies
Samples were run on SDS/PAGE and then transferred on to a nitrocellulose membrane. The membrane was blocked in TBST [TBS (20 mM Tris/HCl, pH 7.5, and 500 mM NaCl) with 0.05 % Tween 20] containing 5 % (w/v) non-fat dried milk for 1 h at room temperature (23) (24) (25) • C). Proteins of interest were probed with corresponding primary antibodies followed by HRP (horseradish peroxidase)-conjugated anti-rabbit or anti-mouse secondary antibodies. Immunoreactive bands were visualized by ECL detection reagents (Applygen Technologies) and analysed with NIH Image 1.62.
The anti-His 6 and anti-GFP antibodies were obtained from MBL. Anti-FLAG antibody was from Applygen Technologies. Anti-PSD95 antibody was obtained from Sigma-Aldrich. AntiMas antibody was from Novus Biologicals. HRP-conjugated anti-GST antibody was obtained from GE Healthcare. Anti-ubiquitin was from Santa Cruz Biotechnology. Anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase), anti-actin and HRPconjugated secondary antibodies were obtained from ZSGB-BIO.
Cells and transfection
COS-7, BHK (baby-hamster kidney), LN229 and C6 glioma cells were maintained in DMEM (Dulbecco's modified Eagle's medium) plus 10 % (v/v) FBS and 1 % penicillin/streptomycin (Sigma-Aldrich). Primary cortical neurons were prepared from newborn (under 24 h old) Wistar rats following the method described in [20] . All animal experiments conformed to the institutional and national ethical guidelines for the care and use of animals. The cells were cultured on polylysine-coated glass coverslips in DMEM supplemented with 10 % (v/v) FBS, 10 % (v/v) horse serum and 1 % penicillin/streptomycin. Cell transfection was performed with Lipofectamine TM 2000 (Invitrogen). For cell stable transfection, constructs of GFP, GFPMas wt or GFP-Mas-V325A were transfected into C6 cells respectively with Lipofectamine TM 2000, and selected with the growth medium containing 1200 μg/ml neomycin (Amresco).
GST-fusion protein pull-down assay
GST-fusion proteins were purified from bacteria with glutathioneSepharose 4B beads (Sigma-Aldrich) according to the manufacturer's protocol and resuspended in harvest buffer (50 mM NaCl, 10 mM Hepes, pH 7.4, 5 mM EDTA, 1 mM benzamidine and 0.1 % Tween 20). Equal amounts of beadconjugated GST-fusion proteins were incubated with 20 mg of rabbit brain lysates or equal amounts of His 6 -tagged PDZ domains of PSD95 protein. After incubation with gentle rotation at 4
• C for 3 h, the beads were washed extensively four times with washing buffer (100 mM NaCl, 10 mM Hepes, pH 7.4, 5 mM EDTA, 1 mM benzamidine, 3 % BSA and 0.1 % Tween 20) and once with washing buffer without BSA. Proteins were eluted from the beads by boiling in sample buffer (50 mM Tris/HCl, 100 mM DTT, 2 % SDS, 0.1 % Bromophenol Blue and 10 % glycerol), resolved on SDS/PAGE and analysed by Western blotting.
MALDI-TOF/TOF-MS analysis
Samples from GST pull-down assays were run on SDS/PAGE. Protein bands of interest were excised from Coomassie Bluestained gels, cut into small pieces, washed three times with washing buffer (25 mM ammonium bicarbonate in 50 % acetonitrile, pH 8.0) for 15 min each time. The samples were then reduced and alkylated with DTT (10 mM) and iodoacetamide (55 mM) subsequently. The gel pieces were then subjected to ingel digestion, as described previously [21] . The proteins were then identified by combining peptide mass fingerprints and sequence tags obtained by MALDI-TOF/TOF-MS on an ultrafleXtreme TM MS instrument from Bruker Daltonics. For analysis, 0.5 μl of the digested sample was spotted on to an anchorchip target (Bruker Daltonics). The droplet of the sample was dried at room temperature, and overlaid with 0.5 μl of matrix solution [5 mg/ml L-cyano-4-hydroxycinnamic acid in 50 % acetonitrile and 0.1 % TFA (trifluoroacetic acid)]. The mass spectra were calibrated externally using the monoisotopic [M + H] + ion of peptide calibration standards (Bruker Daltonics). Mass data acquisitions were piloted by flexControl software (version 3.3). The positive MALDI-TOF spectra and MS/MS LIFT spectra of five selected ions were collected, and peak-lists were generated using SNAP peak detection algorithm, signal/noise threshold higher than 6 and TopHat baseline subtraction in FlexAnalysis 3.3 (Bruker Daltonics). The MS spectra and MS/MS spectra were combined by Biotools (Bruker Daltonics), then subjected to the Mascot search engine for protein identification. The mass spectra data were searched in mammalian sequences in the database of NCBInr 20110419, using the following parameters: monoisotopic; peptide mass tolerance, + − 100 p.p.m.; fragment mass tolerance, + − 0.5 Da; missed cleavages, 1.
Blot overlay assay
A blot overlay assay was performed as described previously [22] . Briefly, His 6 -tagged PDZ domains of PSD95-fusion protein were purified, run on SDS/PAGE (10 % gels) and then transferred on to a nitrocellulose membrane (Millipore). The membrane was blocked and incubated with different concentrations of GSTMas-CT fusion proteins overnight at 4
• C. The blots were washed three times and then incubated with HRP-conjugated anti-GST antibody for 1 h at room temperature. GST-Mas-CT fusion protein overlaid on His 6 -PDZ fusion proteins were visualized via ECL and analysed with NIH Image 1.62.
Co-immunoprecipitation
Co-immunoprecipitation was performed as described previously [22] . Briefly, transfected cells were harvested or rabbit brain was homogenized in ice-cold lysis buffer. Supernatants were incubated with anti-FLAG beads (for transfected cells) or anti-PSD95 antibody (for brain lysates) pre-bound to Protein A/Gagarose beads (Calbiochem). The immunoprecipitated proteins were then analysed by Western blotting.
Immunofluorescence co-localization
Immunofluorescence co-localization was performed as described previously [22] . Briefly, BHK cells were transfected with GFP-Mas and/or PSD95 constructs. After fixation and permeabilization, cells were stained with anti-PSD95 antibody and anti-(proteasome 20S α/β) antibody (Abcam) followed by rhodamine-conjugated anti-(mouse IgG) antibody (ZSGB-BIO), Alexa Fluor ® 647-conjugated anti-(rabbit IgG) antibody (Invitrogen) and Hoechst 33258 (5 μg/ml). The cellular distribution of these proteins was then visualized under a confocal microscope (Leica Microsystems, LAS AF-TCS SP5).
PSD95 siRNA knockdown assay
siRNA duplexes directed against PSD95 (siRNA1, 5 -GUUCCA-UCGUUCGCCUCUA-3 , and siRNA2, 5 -GAUAUGAGUUGC-AGGUGAA-3 ), and the scrambled control (5 -UUCUCCGA-ACGUGUCACGU-3 ) were synthesized by Sigma-Aldrich. To perform the siRNA experiments, human glioblastoma LN229 cells with endogenous PSD95 and Mas were grown to 80 % confluence in 35-mm-diameter dishes, whereas the neurons were primarily cultured in vitro for 5-7 days to 60-80 % confluence. Then, 60 nM PSD95 siRNA (mixture of equal amounts of PSD95 siRNA1 and siRNA2) were transfected into cells with 2 μl of Lipofectamine TM 2000 according to the manufacturer's instructions. The cells were then harvested, and protein expression was analysed after 48 h of transfection.
Total RNA extraction and qPCR (quantitative real-time PCR)
Total cellular RNA was extracted with TRIzol ® reagent. The primer sequences for PSD95 were forward, 5 -ACTGCATCCTT-GCGAAGCAAC-3 , and reverse, 5 -CGTCAATGACATGAAG-CACATCC-3 . The primer sequences for Mas were forward, 5 -AACTGGCAGGAACGCCTCA-3 , and reverse, 5 -CTCATC-CGGAAGCACAGGAAC-3 . The Mas and PSD95 mRNA levels were determined using a Brilliant II SYBR ® Green qPCR Master Mix kits respectively (Agilent Technologies), and the samples were normalized with an internal control of GAPDH.
RESULTS
PSD95 was identified as a novel Mas-binding protein
Although the Mas protein is distributed widely in various tissues, it was first cloned from and highly expressed in the brain [16] .
We therefore used rabbit brain lysates to screen Mas-binding proteins in the present study. Mas-CT wt and Mas-V325A mutant GST-fusion proteins were purified and subsequently used in GST pull-down experiments. Equal amounts of bead-conjugated GSTfusion proteins were incubated with rabbit brain tissue lysates. The GST moiety of the GST-Mas-CT fusion protein bound nonspecifically to multiple bands from brain lysates, whereas Mas-CT wt was associated with several additional interacting bands ( Figure 1A ). Interestingly, among these binding proteins, the band indicated with an asterisk (*) was detected with a very weak signal in pull-down complexes of Mas-CT-V325A ( Figure 1A ). The Mas receptor contains a conserved PDZ domain-binding motif (ETVV) at its CT, and mutation of the last valine residue to alanine (V325A) theoretically abolishes the interaction of Mas with PDZ domain proteins. Thus the band indicated with an asterisk was analysed further by MS and was identified as PDZ protein of PSD95 ( Figure 1B ). To verify the interaction of the Mas-CT with PSD95, GST-Mas-CT was used for pull-down assays from rabbit brain lysates, and protein complexes were probed with an anti-PSD95 antibody. As shown in Figure 1 (C), the robust PSD95 protein appeared in the GST-Mas-CT wt pull-down complex and no signal was detected in the Mas-CT-V325A pull-down complex, indicating that GST-Mas-CT wt associated strongly with PSD95, and mutation of the terminal valine residue of Mas to alanine (Mas-V325A) completely abolished this interaction. These findings confirmed the interaction of the Mas-CT with PSD95, and suggested the critical importance of the CT of Mas in mediating this interaction.
Interaction of Mas-CT with PSD95 PDZ1-2
As PDZ1-2 of PSD95 possesses a binding preference that is quite different from that of PDZ3, individual His 6 -PDZ1-2 or His 6 -PDZ3 domain of PSD95-fusion proteins was subjected to pull down by GST-Mas-CT to explore the structural determinants of the Mas-PSD95 interaction (Figure 2A) . A strong PSD95 PDZ1-2 signal was detected in the GST-Mas-CT pull-down complex, and conversely only a very weak signal for His 6 -PDZ3 of PSD95 was detected, suggesting that PDZ1 and PDZ2 were the principal domains mediating the PSD95-Mas interaction.
As the ETVV motif of the Mas-CT is a canonical class I PDZ domain-binding motif, we explored further the Mas-CT-PSD95 association by generating a series of mutations of Mas-CT with alanine substitutions in this motif. Mas-CT wt (ETVV) or its various mutants (ATVV, EAVV, ETAV and ETVA) was incubated with His 6 -PDZ1-2 of PSD95, and the precipitation complexes were detected with an anti-His 6 antibody ( Figure 2B ). ETVV was strongly associated with His 6 -PDZ1-2 of PSD95, whereas the mutation of any of the terminal four amino acid residues to alanine almost completely impaired this interaction.
In addition to the fusion protein pull-down experiments, we used the reverse experiments to assess the binding ability of the Mas-PSD95 complex via a blot overlay assay using different concentrations of GST-Mas-CT proteins (5-800 nM). The results were plotted in Figure 2 (C), which estimated the binding affinity of PSD95 PDZ1-2 to the Mas-CT as 40 nM, revealing the relatively high affinity of this interaction. Consistent with the GST pull-down results, PSD95 PDZ3 did not detectably associate with Mas-CT according to the overlay assay (results not shown).
PSD95 interacts with Mas in cells and native tissues
The interaction between full-length Mas and full-length PSD95 within cells was examined using co-immunoprecipitation assays.
Figure 1 Proteomic screen defines the Mas-binding partners and identifies PSD95 as a novel Mas-associated protein
(A) Screening of Mas-CT-binding partners by GST pull-down assay. Purified GST-Mas-CT fusion proteins were adsorbed to glutathione-agarose beads, and used to pull down lysates of rabbit brain. The precipitates were run on SDS/PAGE gels and then visualized by Coomassie Blue staining. Positions of molecular-mass markers are shown on the left in kDa. (B) PSD95 was analysed as a novel Mas-associated protein by MS. The protein band indicated in (A) with an asterisk (*), which strongly bound to the Mas-CT wt was excised from the Coomassie Blue-stained gel and analysed by MS. Panel a, peptide mass fingerprinting of the protein band indicated in (A) with the asterisk generated by tryptic digestion. Panel b, MS/MS spectra of the peptide ion with m/z 1618.968, which selected from MS spectra of the protein band indicated in (A) with the asterisk. MS/MS analysis suggested that this protein band was PSD95. Intensity (intens.) is measured in arbitrary units (a.u.). (C) PSD95 was identified as Mas-CT-associated protein by Western blotting. Equal amounts of purified GST-fusion protein beads of Mas-CT wt or its V325A mutant were used respectively for pull down of rabbit brain lysates, and the pull-down complex was subjected to Western blotting with an anti-PSD95 antibody (upper panel). Coomassie Blue staining revealed equal loading of the fusion proteins (lower panel). Molecular masses are indicated in kDa.
The expression levels of FLAG-Mas wt and FLAG-Mas-V325A were adjusted to similar levels through transfection with different amounts of the respective constructs. As expected, PSD95 was strongly co-immunoprecipitated with FLAG-Mas wt, whereas minimal amounts were detected in the FLAG-Mas-V325A immunoprecipitation complexes, indicating that full-length Mas associates with PSD95 in cells, and again revealing the importance of the terminal valine residue for their interaction ( Figure 3A) . We examined further the interaction of Mas with PSD95 in the absence and presence of agonist stimulation. As a result, PSD95 was robustly co-immunoprecipitated with FLAG-Mas, but treatment with Ang- (1-7) , an agonist of Mas receptor, had no detectable effect on the interaction of Mas receptor with PSD95 protein ( Figure 3B ). To examine the interaction of endogenous Mas and PSD95 in rabbit brain tissue, solubilized brain lysates were incubated with anti-PSD95 antibody linked to Protein A/Gagarose beads. A robust Mas signal was detected in PSD95 coimmunoprecipitation complexes, but no signal was detected in the control samples ( Figure 3C ), which indicated the existence of a physical complex between Mas and PSD95 in native tissues.
The potential co-localization of Mas and PSD95 in cultured cells was examined via immunofluorescence microscopy. BHK cells were used during these experiments in order to better visualize cell morphology. BHK cells were co-transfected with constructs of PSD95 as well as GFP-Mas wt or GFPMas-V325A. In cells transfected with these constructs alone, PSD95 was located exclusively in the plasma membrane, forming a smooth rim around the cell [23, 24] (Figure 4B, panel b) . When GFP-tagged Mas was expressed alone, it was observed predominantly in the cytoplasm [25] (Figure 4A, panel a) , partly overlapping with the proteasome 20S α/β subunits ( Figure 4A , panel e). When Mas wt was co-expressed with PSD95, a significant fraction of total Mas wt was retained in the plasma membrane ( Figure 4C, panel a) , where it exhibited excellent co-localization with PDS95 ( Figure 4C, panel d) . Conversely, when the Mas mutant was co-expressed with PSD95, the mutant receptors remained almost exclusively distributed in the cytoplasm ( Figure 4D, panel a) , exhibiting little overlap with PSD95 immunolabelling ( Figure 4D, panel d) . However, a remarkable co-localization of Mas-V325A and proteasome 20S α/β subunits was observed in proteasome ( Figure 4D , panel e) compared with no co-localization of Mas wt and proteasome 20S α/β subunits ( Figure 4C , panel e). These data were in agreement with the findings of co-immunoprecipitation experiments and confirmed the interaction between Mas and PSD95 in cells. These data further indicated that PSD95-Mas association (A) Mas-CT specifically binds to the PDZ1-2 domains of PSD95. GST-Mas-CT beads were used to pull down His 6 -PSD95 PDZ1-2-or PDZ3-fusion proteins. Precipitates were subjected to Western blotting with an anti-His 6 antibody. A robust signal corresponding to the PDZ1-2 domains of PSD95 was detected in the GST-Mas-CT pull-down complexes (top panel). Western blotting and Coomassie Blue staining showed equal loading of the fusion proteins respectively (middle and bottom panels). (B) Mas-CT selectively associates with the PDZ1-2 domains of PSD95. Purified GST-fusion proteins corresponding to either Mas-CT wt (denoted by its last four amino acids, ETVV) or point-mutated versions of the wt (denoted by sequential replacement of each of the last four amino acids with alanine) were used to pull down the His 6 -tagged PSD95 PDZ1-2 domains from the bacterial lysates. Pull-down precipitates were subjected to Western blotting with an anti-His 6 antibody. Coomassie Blue staining confirmed that equivalent amounts of various GST-fusion proteins were present in each sample. (C) The overlay assay results show a relatively high affinity between Mas-CT and PSD95 PDZ1-2. Nitrocellulose membrane containing 1 μg of His 6 /S-tagged PSD95 PDZ1-2 was incubated with GST-Mas-CT at different concentrations ranging from 5 to 800 nM. PSD95 PDZ1-2-specific binding did not increase significantly between 400 and 800 nM, therefore the binding observed at 800 nM was defined as the 'maximal' binding. inhibits subcellular localization of Mas with proteasome in the cytoplasm.
PSD95 enhances Mas protein stabilization
The functional significance of the Mas-PSD95 interaction was explored next. We observed that the expression level of Mas was significantly increased when it was co-expressed with PSD95 compared with Mas expressed alone (equal doses of Mas constructs were used in the transfection) ( Figure 5A ), suggesting that the Mas-PSD95 interaction may play a role in the regulation of Mas expression levels. To examine whether the effect of PSD95 on Mas expression was dependent on the Mas-PSD95 interaction, COS-7 cells were transfected with Mas wt or Mas-V325A in the presence or absence of PSD95, and Mas protein levels were determined by Western blotting. As shown in Figure 5 (B), PSD95 overexpression significantly increased the protein level of Mas wt, but not that of the Mas-V325A mutant, indicating that disruption of the Mas-PSD95 interaction suppressed the Mas protein expression up-regulated by PSD95.
To verify the results of the PSD95-overexpression experiments, endogenous PSD95 expression was knocked down in C6 (results not shown) and LN229 ( Figure 5C ) cells. RNAi-mediated knockdown of PSD95 caused a significant reduction in the PSD95 expression of approximately 70 % in LN229 cells. Meanwhile, the protein expression of Mas was co-ordinately decreased by approximately 30 % of the scrambled control (P < 0.05) ( Figure 5C ). These results confirmed that PSD95 increases the expression of Mas. To test further whether endogenous Mas protein could also be modulated by PSD95 expression in primary cultured cells, PSD95 was knocked down in primary neuron cells with PSD95-specific siRNA, which resulted in a significant reduction in PSD95 expression of approximately 30 % and a concomitant decrease in endogenous Mas of approximately 30 % (Figure 5D ). Taken together, the results of our PSD95-overexpression and -knockdown experiments demonstrated that the regulation of Mas protein expression is mediated by its interaction with PSD95.
To explore the mechanism of Mas expression regulated by PSD95, the Mas mRNA levels were examined next. As shown in Figure 6 (A), Mas mRNA levels did not decrease after knocking down PSD95 expression in human glioblastoma LN229 cells, indicating that the regulation of Mas protein expression by PSD95 is independent of Mas mRNA transcription, and may involve the post-translational modification of Mas based on its direct interaction with PSD95.
To test this hypothesis, we measured the turnover rate of the Mas protein upon binding to PSD95. COS-7 cells transfected with Mas constructs were treated with different doses of the protein synthesis inhibitor CHX (cycloheximide) for 12 h. Figure 6(B) shows the dose-dependent decrease in Mas protein levels after exposure to CHX (from 0 to 50 ng/μl). Because no significant change in Mas protein expression was detected in response to CHX doses between 25 and 50 ng/μl, the 25 ng/μl CHX dose was used for subsequent experiments with COS-7 cells transiently transfected with various combinations of constructs including Mas wt, Mas-V325A, Mas wt-PSD95 or Mas-V325A-PSD95. The cells were harvested at different time points as indicated in Figure 6 (C), and the protein levels of Mas and PSD95 were assessed by Western blotting. The protein expression levels of Mas significantly decreased in a time-dependent manner when Mas was expressed alone. When PSD95 was overexpressed, however, the Mas wt protein turnover rate was significantly reduced (P < 0.05), and Mas wt protein levels were significantly higher than that of similarly treated Mas-V325A. These data indicated that PSD95-mediated up-regulation of Mas protein expression was independent of Mas mRNA transcription, and Mas protein stabilization was enhanced by interaction with PSD95.
PSD95 enhances Mas expression by attenuation of the ubiquitin-proteasome proteolytic Mas protein
The effect of PSD95 on the stabilization of the Mas protein was probably mediated by the inhibition of Mas protein degradation. Intracellular protein degradation relies mainly on the lysosomal degradation and ubiquitin-proteasome pathways. To explore the mechanism of Mas protein expression up-regulated by PSD95, C6 cells stably transfected with Mas constructs were treated with chloroquine (100 μM), a lysosome inhibitor, or MG132 (10 μM), a proteasome inhibitor. As shown in Figure 7 (A), a marked increase in Mas protein expression was detected in response to MG132 treatment, whereas no detectable increase in Mas protein expression was observed in chloroquine-treated cells, suggesting that the degradation of the Mas protein occurs via the proteasome pathway. To confirm further the involvement of the proteasome degradation pathway, C6 cells stably transfected with Mas constructs were treated with different doses of MG132. As shown in Figure 7 (B), MG132 dose-dependently elevated Mas protein expression, which reached saturation levels with 10 μM MG132. We also detected degradation of endogenous Mas protein in C6 cells, in which Mas receptor moderately expressed. C6 cells were treated with MG132 for different times (0, 3, 9 and 12 h). As shown in Figure 7 (C), endogenous Mas protein levels significantly increased time-dependently. These data indicated further that the degradation of the Mas protein occurs via the proteasome pathway.
To verify further that the PSD95 regulation of Mas stabilization is mediated by the ubiquitin-proteasome pathway, we assessed the effect of PSD95 expression on Mas protein ubiquitination in COS-7 cells. FLAG-Mas wt or its V325A mutant with the same dose of Mas constructs was transfected into COS-7 cells in the presence or absence of PSD95. The cells were treated with MG132 for 12 h to inhibit the degradation of ubiquitin-conjugated Mas and facilitate the detection of the ubiquitinated Mas molecule. The similar levels of FLAG-Mas proteins were exhibited in all lanes after Western blotting ( Figure 7D) , as PSD95 has little or no effect on total Mas protein expression levels when cells were pretreated with MG132. The Mas protein was then immunoprecipitated with the anti-FLAG antibody, and the ubiquitination of Mas was analysed by immunoblotting with an anti-ubiquitin antibody. As shown in Figure 7 (D), a remarkable amount of ubiquitinated Mas wt protein was detected in cells that were not transfected with PSD95, whereas PSD95 co-expression reduced Mas wt ubiquitination (P < 0.05). In contrast, the ubiquitination of the Mas-V325A mutant was not affected by PSD95 co-expression in comparison with that of mutant Mas expression alone, suggesting that Mas ubiquitination was inhibited by the interaction with PSD95. These data were consistent with the results from our confocal microscopy data that Mas partly co-localized with proteasomes in the cytoplasm, and the receptor was anchored in the plasma membrane by PSD95 co-expression, inhibiting Mas co-localization with the proteasome. Taken together, these data indicate that PSD95 may inhibit Mas receptor ubiquitination, thus suppressing the proteasome pathway-mediated degradation of the receptor and enhance Mas protein stabilization.
DISCUSSION
The functions and signalling mechanisms of the Mas receptor have been studied extensively. However, much less attention has been paid to the intracellular regulation of Mas protein.
In the present study, we screened Mas-binding proteins by GST (A) Mas protein levels were enhanced when it was co-expressed with PSD95. COS-7 cells were transfected with equal amounts of Mas wt constructs in the presence or absence of Myc-PSD95. The Mas protein was examined by Western blotting. GAPDH was used as a loading control. (B) PSD95 overexpression enhanced Mas protein expression dependent on the association of Mas with PSD95. COS-7 cells were transfected with FLAG-Mas wt or FLAG-Mas-V325A constructs in the presence or absence of PSD95. The Mas proteins were detected using the anti-FLAG antibody. Actin was used as a loading control. (C) Knockdown of endogenous PSD95 expression in LN229 cells decreased Mas protein expression. LN229 cells were transfected with either PSD95 siRNA or its scrambled control (NC). Cells were harvested 48 h after transfection, and total cellular RNA was extracted using TRIzol ® reagent, or total protein was extracted with protein lysis buffer. The PSD95 mRNA levels were determined by qPCR, and the PSD95 and Mas proteins were detected using the anti-PSD95 antibody and anti-Mas antibody (* P < 0.05 compared with NC). (D) Endogenous Mas protein expression in primary neuron cells was regulated by PSD95. Primary neuron cells were transfected with either PSD95 siRNA or its scrambled control (NC). The cells were harvested 48 h after transfection. Total cellular RNA was extracted using TRIzol ® reagent, and PSD95 mRNA levels were assessed by qPCR. Total protein was extracted with protein lysis buffer, and PSD95 and Mas protein levels were detected using the anti-PSD95 antibody and anti-Mas antibody. Results in each histogram are means + − S.D. obtained by quantification of the blots from three individual experiments (*P < 0.05 compared with NC). Molecular masses are indicated in kDa. pull-down combined with MS, and identified PSD95 as a novel binding protein of Mas receptor. PSD95 (also named SAP90 and DLG4) is a PDZ domain-containing protein that possesses three tandem PDZ domains linked to an SH3 (Src homology 3) domain and C-terminal GK (guanylate kinase) region. Mas specifically interacted via its CT with the PDZ1-2, but not PDZ3, domain of PSD95, which was supported by the results of GST pull-down (Figure 2 ), co-immunoprecipitation ( Figure 3 ) and confocal co-localization ( Figure 4 ). PSD95 PDZ1-2 domain has been defined to interact with the consensus sequence (S/T)XV-COOH, where X can represent any residue. However, mutation of Mas's valine residue at the − 1 position to alanine resulted in complete elimination of the Mas-PSD95 interaction ( Figure 2B ). This observation is not unique and has been reported previously in other PDZ domains, such as Erbin-PDZ and ZO1-PDZ1 [26] . It is clear that other residues also contribute to specificity for a given PDZ domain, because the (S/T)XV motif in some proteins is insufficient for binding any of the PDZ domains of PSD95 such as the neuronal inwardly rectifying K + channels Kir3.2 and Kir3.3 (the C-terminal sequence is ESKV in both cases) [27] and the Na + channel Na v 1.5 (ESIV motif) [28] . This indicates that some other residues may also affect the binding affinity of the given PDZ domain with the (S/T)XV motif, and it is possible that these residues or peptide sequence would not allow the single mutation of valine to alanine at − 1 as is the case in the present study. However, this hypothesis needs further study.
PDZ domains are modular protein-interaction domains that play multiple roles in the regulation of the function and signalling of GPCRs [18] . The PDZ protein MAGI-2 (membraneassociated guanylate kinase inverted 2) associates with β 1 AR (β 1 -adrenergic receptor) and promotes its internalization, whereas the PDZ protein CAL reduces β 1 AR cell-surface expression and regulates its vesicular transport [29] . Recent evidence suggests that protein stabilization may be enhanced by binding with some PDZ proteins. E6 protein expression in high-risk human papillomaviruses is increased in the presence of the PDZ protein hScrib [30] . A previous study from our group showed that the PDZ protein CAL interacts with mGluR5a (metabotropic glutamate receptor 5a) and enhances receptor expression by inhibiting its ubiquitination [20] .
In the present study, overexpression of PSD95 was shown to upregulate Mas protein expression ( Figures 5A and 5B) . Conversely, siRNA-mediated knockdown of PSD95 significantly reduced Mas protein levels ( Figures 5C and 5D ). These results indicated that the interaction between PSD95 and Mas regulates the expression of the Mas receptor. Our data demonstrate further that PSD95 regulation of Mas expression does not occur at the transcriptional level, but rather by increasing Mas stabilization ( Figure 6 ).
Intracellular protein degradation relies mainly on the lysosomal or proteasome pathways. In the present study, we have shown that Mas degradation was robustly retarded by MG132, a specific proteasome inhibitor, in time-and dose-dependent manners ( Figures 7B and 7C) . Proteins are targeted for degradation by the proteasome via ubiquitination. Our results showed that PSD95 overexpression impaired the ubiquitination of Mas wt, but did not affect the Mas-V325A mutant ( Figure 7D ), indicating that the proteasome-mediated degradation of Mas is suppressed by its association with PSD95. In a previous study, we found that the PDZ protein NHERF1 (Na + /H + -exchanger regulatory factor 1) blocked the association of PTEN (phosphatase and tensin homologue deleted on chromosome 10) with the ubiquitin E3 ligase NEDD4 (neural-precursor-cell-expressed developmentally down-regulated 4), thus inhibiting the ubiquitination-dependent PTEN degradation pathway [31] . Sequencing analysis indicates that Mas possesses several conserved lysine-rich regions at its CT (the last 40 amino acids of Mas-CT are S 286 KKKRFKESL-KVVLTRAFKDEMQPRRQKDNCNTVTVETVV 325 ), and Mas Lys 313 is most likely to be one of the Mas protein ubiquitination sites by predication using UbPred (http://www.ubpred.org). It is possible that the PSD95-Mas interaction may also interfere with the binding of an ubiquitin E3 ligase to Mas-CT, resulting in the inhibition of Mas ubiquitination and suppression of receptor degradation. However, this possibility needs to be investigated further.
The Mas protein is expressed in different brain areas including the hippocampus, forebrain and piriform cortex [32] . PSD95 is also expressed in the prefrontal cortex and hippocampus of the brain [33, 34] . Together with our current results, this suggests that Mas and PSD95 may physically interact in the brain, where the association could have a potentially important role. The Mas receptor in the brain is known to be involved in neural plasticity, memory, anxiety and LTP associated with PI3K/Aktmediated nitric oxide release and c-Src activation [12, 35] . Indeed, by binding nNOS (neuronal nitric oxide synthase) or Src PTKs (protein tyrosine kinases), PSD95 can also regulate the learning, memory and neural plasticity and mediate LTP in synapses of the hippocampus [36] [37] [38] . Because PSD95 can associate directly with Mas and nNOS respectively, it may function as a scaffold protein to mediate the formation of a Mas-PSD95-nNOS macromolecular complex involved in the regulation of Ang-(1-7)-Mas signalling and its neurobiological functions. However, this possibility needs to be explored further.
In the brain, hypothalamic Ang-(1-7) plays an important role in blood pressure regulation via its receptor Mas [39] . The SHR (spontaneously hypertensive rat) exhibits a chronically stimulated brain angiotensin system and cerebrovascular hypertrophy [40] . Saavedra and colleagues explored species differences in gene expression in 12-week-old SHR male rats and WKY (Wistar Kyoto) rats using the Affymetrix Rat Genome U34 Array (GEO ID: GDS2070), and found no statistically significant differences in Mas mRNA expression in brain microvascular tissue (P = 0.17), whereas PSD95 mRNA expression was significantly reduced by approximately 47 % in SHR compared with WKY male rats (P = 0.02) [40] . The present results, however, showed that PSD95 down-regulation destabilized the Mas protein resulting in low Mas receptor levels ( Figure 5 ). Thus one possible molecular mechanism of hypertension in SHR is that the low level of PSD95 mRNA expression may weaken the anti-hypertension effect of Mas as a result of Mas receptor destabilization and down-regulation. Further studies are necessary to confirm this hypothesis.
In summary, the PDZ protein PSD95 was identified as a novel Mas receptor-interacting molecule. The C-terminus of Mas specifically interacts with the PDZ1-2 domain of PSD95. Functional studies showed that Mas protein expression was upregulated through its interaction with PSD95, which suppressed Mas ubiquitination and proteasomal degradation. Therefore our findings reveal a new mechanism for the regulation of Mas protein expression by PSD95 involving the inhibition of ubiquitinationdependent degradation. The elucidation of this mechanism of PSD95-mediated regulation may help to clarify further the functions of the Mas receptor in the central nervous system.
